…
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -63.31M | 0.92M | -10.52M | -17.73M | -17.23M |
| Minority interest | - | - | - | 0.14M | 0.40M |
| Net income | -60.21M | 0.79M | -11.31M | -17.35M | -13.95M |
| Selling general administrative | 9.49M | 46.42M | 41.47M | 32.24M | 24.43M |
| Selling and marketing expenses | 1.21M | 2.68M | 3.26M | 2.66M | 2.24M |
| Gross profit | 3.97M | 23.63M | 59.41M | 34.99M | 21.31M |
| Reconciled depreciation | - | 4.20M | 5.35M | 4.90M | 3.21M |
| Ebit | -13.06M | 2.85M | -8.38M | -16.19M | -16.81M |
| Ebitda | -11.93M | 7.05M | -3.03M | -11.29M | -13.59M |
| Depreciation and amortization | 1.12M | 4.20M | 5.35M | 4.90M | 3.21M |
| Operating income | -6.73M | 2.70M | -7.03M | -16.19M | -18.33M |
| Other operating expenses | 69.73M | 119.41M | 106.40M | 83.94M | 55.63M |
| Interest expense | 2.87M | 1.93M | 2.13M | 1.54M | 0.42M |
| Tax provision | - | 0.13M | 0.79M | -0.24M | -2.86M |
| Interest income | - | 0.16M | 0.05M | 0.00M | 0.04M |
| Net interest income | - | -1.77M | -2.08M | -1.54M | -0.38M |
| Income tax expense | 0.01M | 0.13M | 0.79M | -0.24M | -2.86M |
| Total revenue | 62.99M | 122.11M | 97.96M | 67.75M | 38.77M |
| Total operating expenses | 10.71M | 20.93M | 67.84M | 53.15M | 39.62M |
| Cost of revenue | 59.02M | 98.47M | 38.55M | 32.76M | 17.47M |
| Total other income expense net | -56.58M | -1.77M | -3.48M | -31.51M | 1.47M |
| Net income from continuing ops | - | 0.79M | -11.31M | -17.49M | -14.37M |
| Net income applicable to common shares | - | 0.79M | -11.31M | -17.35M | -13.95M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 39.84M | 98.78M | 95.91M | 78.44M | 80.92M |
| Intangible assets | - | - | 19.80M | 18.96M | 19.93M |
| Other current assets | 21.37M | 2.08M | 0.12M | 0.12M | 0.13M |
| Total liab | 41.46M | 47.20M | 47.45M | 43.89M | 32.07M |
| Total stockholder equity | -1.62M | 51.58M | 48.46M | 34.55M | 48.45M |
| Other current liab | 18.59M | 14.65M | 16.17M | 16.30M | 12.74M |
| Common stock | 123.67M | 116.55M | 115.41M | 91.81M | 90.99M |
| Capital stock | - | - | 115.41M | 91.81M | 90.99M |
| Retained earnings | -132.30M | -72.09M | -72.88M | -61.58M | -44.23M |
| Other liab | - | - | 1.96M | 0.67M | 1.21M |
| Good will | - | 46.34M | 46.61M | 37.38M | 34.62M |
| Other assets | - | 0.00M | 0.02M | 0.14M | 0.48M |
| Cash | 10.30M | 15.58M | 14.20M | 7.58M | 7.15M |
| Total current liabilities | 22.90M | 45.67M | 33.17M | 35.26M | 23.26M |
| Current deferred revenue | - | 15.14M | 12.05M | 7.51M | 5.17M |
| Net debt | 7.09M | -2.97M | -1.11M | 5.84M | 2.01M |
| Short term debt | 0.08M | 12.61M | 0.78M | 5.45M | 1.57M |
| Short long term debt | - | - | - | 4.07M | 0.30M |
| Short long term debt total | 17.40M | 12.61M | 13.09M | 13.41M | 9.16M |
| Other stockholder equity | - | - | -42.53M | -30.23M | -46.76M |
| Property plant equipment | - | - | 1.37M | 3.47M | 4.57M |
| Total current assets | 39.50M | 32.51M | 28.11M | 18.48M | 21.32M |
| Long term investments | - | - | - | 0.13M | 0.12M |
| Net tangible assets | - | - | -17.95M | -21.80M | -6.10M |
| Short term investments | - | - | 0.12M | 0.12M | 0.13M |
| Net receivables | 7.82M | 14.86M | 11.73M | 9.05M | 12.46M |
| Long term debt | - | - | 12.05M | 7.06M | 6.09M |
| Inventory | - | - | 2.06M | 1.73M | 1.58M |
| Accounts payable | 4.22M | 3.27M | 4.17M | 6.00M | 3.79M |
| Accumulated other comprehensive income | 7.01M | 7.13M | 5.93M | 4.32M | 1.69M |
| Non currrent assets other | 0.02M | 0.02M | 0.02M | 0.14M | 0.48M |
| Non current assets total | 0.34M | 66.27M | 67.80M | 59.96M | 59.60M |
| Capital lease obligations | - | - | 1.05M | 2.28M | 2.77M |
| Long term debt total | - | - | 12.31M | 7.96M | 7.60M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | - | -2.80M | -3.23M | -0.29M | -43.89M |
| Change to liabilities | - | - | 3.64M | 7.68M | -4.15M |
| Total cashflows from investing activities | -2.18M | -2.80M | -3.23M | -0.29M | -43.89M |
| Net borrowings | - | - | -1.23M | 1.92M | 5.85M |
| Total cash from financing activities | 11.34M | -0.83M | 12.42M | 1.86M | 51.24M |
| Change to operating activities | - | - | -0.47M | -0.28M | 0.18M |
| Net income | -60.21M | 0.79M | -11.31M | -17.35M | -13.95M |
| Change in cash | -5.27M | 1.38M | 6.62M | 0.43M | -5.19M |
| Begin period cash flow | 15.58M | 14.20M | 7.58M | 7.15M | 12.35M |
| End period cash flow | 10.30M | 15.58M | 14.20M | 7.58M | 7.15M |
| Total cash from operating activities | -14.37M | 5.19M | -1.45M | -0.24M | -12.54M |
| Issuance of capital stock | - | - | 14.60M | - | 47.53M |
| Depreciation | 3.19M | 4.20M | 3.27M | 3.09M | 2.00M |
| Other cashflows from investing activities | - | -1.77M | - | 0.02M | -43.49M |
| Dividends paid | - | - | - | 14.60M | 6.78M |
| Change to account receivables | - | -3.02M | -1.78M | 3.41M | -1.70M |
| Sale purchase of stock | - | 0.00M | -0.95M | -0.05M | -2.44M |
| Other cashflows from financing activities | - | -0.83M | -1.23M | 2.21M | 13.15M |
| Change to netincome | - | - | 2.57M | 1.40M | 3.87M |
| Capital expenditures | 0.00M | 1.83M | 0.18M | 0.31M | 0.39M |
| Change in working capital | - | -2.78M | -1.78M | 3.41M | -1.70M |
| Stock based compensation | 1.83M | 2.57M | 2.20M | 1.22M | 1.28M |
| Other non cash items | 40.82M | 2.98M | 6.58M | 14.02M | -0.60M |
| Free cash flow | -14.37M | 3.35M | -1.63M | -0.55M | -12.94M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PME Pro Medicus Ltd |
-4.52 2.18% |
202.79 | 81.98 | 106.38 | 83.13 | 43.70 | 74.38 | 95.34 |
| 4DX 4DMEDICAL Ltd |
-0.06 2.53% |
2.31 | - | - | 205.57 | 8.53 | 170.03 | -7.29 |
| CGS Cogstate Ltd |
0.12 3.30% |
3.76 | 33.80 | 27.86 | 9.59 | 6.95 | 6.35 | 19.27 |
| AYA ARTRYA Ltd |
-0.14 3.91% |
3.44 | - | - | 20505.14 | 7.00 | 16927.51 | 0.33 |
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Ms. Ruba El-Afifi | Chief Operating Officer | NA |
| Mr. John Ciccio | Chief Exec. Officer of Adheris | NA |
| Mr. Rick Ratliff | CEO, MD & Director | NA |
| Ms. Ancila Desai B.Com., C.A., M.B.A. | Chief Financial Officer | NA |
| Mr. Craig Schnuriger | Acting Chief Technology Officer | NA |
| Ms. Naomi Lawrie | Company Sec. & Gen. Counsel | NA |
| Mr. Wayne Marinoff | EGM of Sales & Marketing | NA |
| Mr. Jamal Butt | Chief Exec. Officer of UK | NA |
| Mr. James M. Rotsart R.Ph. | Exec. VP of US & Client Relations | NA |
| Mr. Richard Ratliff | CEO, MD & Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.